- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1317EUR$1,500USD£1,146GBP
- Report
- December 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Report
- February 2026
- 179 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- November 2025
- 200 Pages
Global
From €6978EUR$7,950USD£6,071GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €2194EUR$2,500USD£1,909GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1756EUR$2,000USD£1,527GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1317EUR$1,500USD£1,146GBP
- Report
- August 2024
- 82 Pages
Japan
From €3072EUR$3,500USD£2,673GBP
Interleukin 13 (IL-13) is a cytokine that plays a role in the regulation of the immune system. It is involved in the development of immune disorders such as asthma, allergies, and inflammatory bowel disease. IL-13 is a key target for drug development in the immune disorders market, as it has been shown to reduce inflammation and improve symptoms.
IL-13 is a promising target for drug development due to its ability to modulate the immune system. It has been shown to reduce inflammation and improve symptoms in a variety of immune disorders. Additionally, IL-13 has been shown to be effective in combination with other drugs, making it a viable option for combination therapies.
Several companies are developing drugs targeting IL-13 for the treatment of immune disorders. These include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more